РОЛЬ КОМБИНИРОВАННОЙ ПОЗИТРОННОЙ ЭМИССИОННОЙ КОМПЬЮТЕРНОЙ ТОМОГРАФИИ С 18-ФТОРДЕЗОКСИГЛЮКОЗОЙ В ВЕДЕНИИ БОЛЬНЫХ ДИФФЕРЕНЦИРОВАННЫМ РАКОМ ЩИТОВИДНОЙ ЖЕЛЕЗЫ
https://doi.org/10.20862/0042-4676-2017-98-2-103-110
Аннотация
Об авторах
Т. М. Гелиашвили
ГБУЗ «Челябинский областной клинический онкологический диспансер»
Россия
Россия
врач-радиотерапевт,
ул. Блюхера, 42, Челябинск, 454087
А. В. Важенин
ГБУЗ «Челябинский областной клинический онкологический диспансер»;
ФГБОУ ВО «Южно-Уральский государственный медицинский университет» Минздрава России
Россия
Россия
д. м. н., профессор, академик РАН, заведующий кафедрой онкологии, лучевой диагностики и лучевой терапии, главный врач,
ул. Блюхера, 42, Челябинск, 454087;
ул. Воровского, 64, Челябинск, 454092
Н. Г. Афанасьева
ГБУЗ «Челябинский областной клинический онкологический диспансер»
Россия
Россия
к. м. н., заведующая Центром позитронной эмиссионной томографии,
ул. Блюхера, 42, Челябинск, 454087
Список литературы
1. Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа; 2007. [Chissov V.I., Dar'yalova S.L. Oncology. Moscow: GEOTARMedia; 2007 (in Russ.).]
2. Sherman S.I. Thyroid carcinoma. Lancet. 2003; 361 (9356): 501–11.
3. Sipos J.A., Mazzaferri E.L. Thyroid cancer epidemiology and prognostic variables. Clinical. Oncology. 2010; 22 (6): 395–404.
4. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., Pereira A.M., Romijn J.A., Smit J.W. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocr. Metab. 2006; 91 (1): 313–9.
5. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006; 295 (18): 2164–7.
6. Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J. Nucl. Med. 1987; 28 (5): 910–4.
7. Feine U., Lietzenmayer R., Hanke J.P., Held J., Wohrle H., Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med. 1996; 37 (9): 1468–72.
8. Salvatori M., Biondi B., Rufini V. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiatedthyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur. J. Endocr. 2015; 173 (3): 115–30.
9. Padovani R.P., Robenshtok E., Brokhin M., Tuttle R.M. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid. 2012; 22 (8): 778–83.
10. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26 (1): 1–133.
11. Treglia G., Bertagna F., Piccardo A., Giovanella L. 131-I-whole-body scan or 18-FDG-PET/CT for patients with elevated thyroglobulin and negative ultrasound? Clin. Translat. Imag. 2013; 1 (3): 175–83.
12. Leboulleux S., El Bez I., Borget I., Elleuch M., Deandreis D., Al Ghuzlan A. et al. Post-radioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid. 2012; 22 (8): 832–8.
13. Dong M.J., Liu Z.F., Zhao K., Ruan L.X., Wang G.L., Yang S.Y. et al. Value of 18F-FDG-PET/
14. PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan. Meta-analysis. Nucl. Med. Commun. 2009; 30 (8): 639–50.
15. Giovanella L. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Expert Rev. Endocr. Metabol. 2012; 7 (1): 35–43.
16. Masson-Deshayes S., Schvartz C., Dalban C., Guendouzen S., Pochart J.M., Dalac A. et al. Prognostic value of (18)F-FDG PET/CT metabolic parameters in metastatic differentiated thyroid cancers. Clin. Nucl. Med. 2015; 40 (6): 469–75.
17. Robbins R.J., Wan Q., Grewal R.K., Reibke R., Gonen M., Strauss H.W. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography scanning. J. Clin. Endocr. Metabol. 2006; 91 (2): 498–505.
18. Deandreis D., Al Ghuzlan A., Leboulleux S. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr. Relat. Cancer. 2011; 18 (1): 159–69.
19. Wang W., Larson S.M., Fazzari M., Tickoo S.K., Kolbert K., Sgouros G. et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J. Clin. Endocr. Metabol. 2000; 85 (3): 1107–13.
20. Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur. J. Nucl. Med. Mol. Imag. 2012; 39 (9): 1373–80.
21. Lee J.W., Lee S.M., Lee D.H., Kim Y.J. Clinical utility of 18FFDG PET/CT concurrent with
22. I therapy in intermediate-tohigh-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J. Nucl. Med. 2013; 54 (8): 1230–6.
23. Gaertner F.C., Okamoto S., Shiga T., Ito Y.M., Uchiyama Y., Manabe O. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for longterm survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake. Clin. Nucl. Med. 2015; 40 (5): 378–83.
24. Bongiovanni M., Paone G., Ceriani L., Pusztaszeri M. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. Clin. Translat. Imag. 2013; 1 (3): 149–61.
25. Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J. Clin. Endocr. Metabol. 1993; 77 (4): 1090–4.
26. Chao Ma, Jiawei Xie, Yanhui Lou, Yanyan Gao, Shuyao Zuo, Xufu Wang. The role of TSH for F-FDGPET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur. J. Endocr. 2010; 163 (2): 177–83.
27. Charles M., Whitworth P.W., Surasi D.S., Pai S.I., Subramaniam R.M. PET/CT in the management of thyroid cancers. Am. J. Roentgenol. 2014; 202 (6): 1316–29.
28. Bertagna F., Biasiotto G., Orlando E., Bosio G., Giubbini R. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Japan. J. Radiol. 2010; 28 (9): 629–36.
29. Schluter B., Bohuslavizki K.H., Beyer W., Plotkin M., Buchert R., Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J. Nucl. Med. 2001; 42 (1): 71–6.
30. Zimmer L.A., McCook B., Meltzer C., Fukui M., Bascom D., Snyderman C. et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolar. Head Neck Surg. 2003; 128 (2): 178–84.
31. Giovanella L., Trimboli P., Verburg F.A., Treglia G., Piccardo A., Foppiani L., Geriani L. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur. J. Nucl. Med. Molec. Imag. 2013; 40 (6): 874–80.
32. Shammas A., Degirmenci B., Mountz J.M., McCook B.M., Branstetter B., Bencherif B. et al. 18FFDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J. Nucl. Med. 2007; 48 (2): 221–6.
Рецензия
Для цитирования:
Гелиашвили Т.М., Важенин А.В., Афанасьева Н.Г. РОЛЬ КОМБИНИРОВАННОЙ ПОЗИТРОННОЙ ЭМИССИОННОЙ КОМПЬЮТЕРНОЙ ТОМОГРАФИИ С 18-ФТОРДЕЗОКСИГЛЮКОЗОЙ В ВЕДЕНИИ БОЛЬНЫХ ДИФФЕРЕНЦИРОВАННЫМ РАКОМ ЩИТОВИДНОЙ ЖЕЛЕЗЫ. Вестник рентгенологии и радиологии. 2017;98(2):103-110. https://doi.org/10.20862/0042-4676-2017-98-2-103-110
For citation:
Geliashvili T.M., Vazhenin A.V., Afanas'eva N.G. ROLE OF COMBINED 18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN THE MANAGEMENT OF PATIENTS WITH DIFFERENTIATED THYROID CANCER. Journal of radiology and nuclear medicine. 2017;98(2):103-110. (In Russ.) https://doi.org/10.20862/0042-4676-2017-98-2-103-110
Просмотров: 36879
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial» («Атрибуция — Некоммерческое использование») 3.0 Непортированная
Послать статью по эл. почте 